| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCT05172258) | National Cancer Institute (NCI) | 2022-07-26 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer (NCT04576091) | National Cancer Institute (NCI) | 2022-07-06 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT04862650) | Marcelo Bonomi | 2021-11-30 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (NCT04671667) | National Cancer Institute (NCI) | 2021-04-27 |
| NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery (NCT04588038) | Hyunseok Kang, MD | 2021-03-12 |
| Oropharynx (OPX) Biomarker Trial (NCT06356272) | Mayo Clinic | 2019-11-15 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer (NCT03468218) | Emory University | 2018-09-18 |
| BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer (NCT02706691) | University of Chicago | 2018-06-01 |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (NCT03422536) | University of Arizona | 2017-12-05 |
| Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer (NCT02388932) | Case Comprehensive Cancer Center | 2015-03-03 |
| Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer (NCT02068157) | Roswell Park Cancer Institute | 2014-04-01 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT02196168) | National Cancer Institute (NCI) | 2014-03-01 |
| Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (NCT01254617) | National Cancer Institute (NCI) | 2011-02-10 |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT01267240) | National Cancer Institute (NCI) | 2010-12-01 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (NCT01256385) | National Cancer Institute (NCI) | 2010-11-01 |
| Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT01064479) | M.D. Anderson Cancer Center | 2010-02-05 |
| Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery (NCT02007200) | National Cancer Institute (NCI) | 2009-07-01 |
| Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT00588770) | National Cancer Institute (NCI) | 2008-08-08 |
| Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (NCT00494182) | M.D. Anderson Cancer Center | 2007-04-25 |
| Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (NCT00458978) | National Cancer Institute (NCI) | 2007-02-01 |